We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+1.03%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$746M
AUM Growth
+$13.3M
Cap. Flow
+$60.1M
Cap. Flow %
8.06%
Top 10 Hldgs %
47.22%
Holding
107
New
21
Increased
25
Reduced
20
Closed
22

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$13.6M
2
MRUS
Merus
MRUS
+$10.9M
3
ARVN icon
Arvinas
ARVN
+$9.84M
4
SYRE icon
Spyre Therapeutics
SYRE
+$9.56M
5
PRQR icon
ProQR Therapeutics
PRQR
+$8.97M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$13.4M
2
ATXS
Astria Therapeutics
ATXS
+$7.98M
3
VRDN icon
Viridian Therapeutics
VRDN
+$7.94M
4
ONC
BeOne Medicines Ltd
ONC
+$7.86M
5
TERN
Terns Pharmaceuticals
TERN
+$5M

Sector Composition

Rank Sector Weight
1 Healthcare 78.04%
2 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$67.5M 9.05%
+750,000
New +$72.7M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.6B
$45.5M 6.1%
1,161,237
+17,216
+2% +$712K
APGE icon
3
Apogee Therapeutics
APGE
$10.1B
$42.2M 5.66%
931,728
+267,530
+40% +$13.6M
ACLX
4
DELISTED
Arcellx
ACLX
$32.6M 4.37%
425,000
+25,000
+6% +$2.16M
ALKS icon
5
Alkermes
ALKS
$8.79B
$31.6M 4.24%
1,100,000
+100,000
+10% +$2.87M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$37.3B
$30.9M 4.14%
1,400,000
– –
VRNA
7
DELISTED
Verona Pharma
VRNA
$30.7M 4.11%
660,000
+10,000
+2% +$375K
MDGL icon
8
Madrigal Pharmaceuticals
MDGL
$12.8B
$25.5M 3.41%
82,500
-17,500
-18% -$4.92M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.88B
$23.5M 3.15%
460,000
+60,000
+15% +$3.36M
NUVL
10
DELISTED
Nuvalent
NUVL
$22.3M 2.99%
285,000
-52,500
-16% -$4.9M
SYRE icon
11
Spyre Therapeutics
SYRE
$8.7B
$19.2M 2.57%
824,328
+325,908
+65% +$9.56M
WVE icon
12
Wave Life Sciences
WVE
$1.12B
$18.6M 2.49%
1,500,000
+100,000
+7% +$1.33M
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$18.4M 2.46%
1,095,924
+130,312
+13% +$2.16M
VERA icon
14
Vera Therapeutics
VERA
$2.76B
$18M 2.41%
425,000
-10,000
-2% -$443K
NRIX icon
15
Nurix Therapeutics
NRIX
$2.4B
$17.7M 2.37%
940,083
+79,684
+9% +$1.83M
MESO
16
PUT
Mesoblast
MESO
$2.24B
$16.6M 2.23%
+838,600
New +$9.29M
MRUS
17
DELISTED
Merus
MRUS
$16.4M 2.19%
389,241
+227,500
+141% +$10.9M
ESTA icon
18
Establishment Labs
ESTA
$2.72B
$12.9M 1.73%
279,445
-11,002
-4% -$480K
ARVN icon
19
Arvinas
ARVN
$517M
$12.1M 1.62%
630,000
+405,000
+180% +$9.84M
INZY
20
DELISTED
Inozyme Pharma
INZY
$11M 1.47%
3,972,318
+1,150,000
+41% +$4.37M
NAMS icon
21
NewAmsterdam Pharma
NAMS
$3.7B
$10.9M 1.46%
425,000
-47,390
-10% -$1.01M
AUTL
22
Autolus Therapeutics
AUTL
$383M
$10.6M 1.42%
4,500,000
– –
GERN icon
23
Geron
GERN
$924M
$7.96M 1.07%
2,250,000
+750,000
+50% +$3M
AMGN icon
24
CALL
Amgen
AMGN
$198B
$7.82M 1.05%
+30,000
New +$8.9M
RZLT icon
25
Rezolute
RZLT
$444M
$7.72M 1.03%
1,575,000
-125,000
-7% -$630K
1
2 3 4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Affinity Asset Advisors held 107 positions worth $746M, up 1.8% from $733M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors deployed $60.1M of net new capital in Q4 2024, opening 21 new positions and adding to 25 existing holdings. Its largest new stake was ProQR Therapeutics: 2,825,000 shares worth $7.49M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Viridian Therapeutics, an estimated $7.94M trimmed.

  • Affinity Asset Advisors's largest Q4 2024 buy was ProQR Therapeutics: 2,825,000 shares worth $7.49M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q4 2024, an estimated $13.6M increase.
  • Affinity Asset Advisors's biggest Q4 2024 reduction was Viridian Therapeutics, cutting an estimated $7.94M.
  • Affinity Asset Advisors fully exited Kura Oncology in Q4 2024, selling an estimated $13.4M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $746M portfolio in Q4 2024.
  • Affinity Asset Advisors opened 21 new positions and closed 22 in Q4 2024.
  • Affinity Asset Advisors's portfolio value rose 1.8% quarter-over-quarter to $746M.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.